Pharma Tariffs Would Result In Fewer, More Expensive Cures

The Trump administration’s tariffs are the talk of the town in Washington. At the end of October, the Senate rejected the administration’s national emergency declaration issued to rationalize the tariffs in a bipartisan vote. On November 5^th, the Supreme Court took up the issue of the constitutionality of the tariffs. If oral arguments are any indication, it did not go well for the administration. Despite the clear opposition, there are voices calling to go even further, potentially threatening America’s supply chain o low-cost, effective medications.